• Mashup Score: 0
    Patient-Reported Outcomes: Are All Patients Equally Engaged? - 8 month(s) ago

    Considering the significant barriers to obtaining accurate and reliable data, investigators should use caution when using PROs to compare groups of different socioeconomic, ethnic, and racial backgrounds, as poor data may lead to erroneous conclusions.

    Source: dailynews.ascopubs.org
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of ASCO
      ASCO

      PROs: Are all patients equally engaged? @laura_tennerMD & @AparGanti explore current studies that have shown there are differences in PRO results between pts of different backgrounds & discuss solutions. https://t.co/SYQn83NfuG #ASCODailyNews #healthequity https://t.co/zaCCGnJwyh

  • Mashup Score: 3
    Treatment Choice: How to Sequence New Antibody-Drug Conjugates in HER2-Negative Breast Cancer - 8 month(s) ago

    Probably one of the most heated debates currently is on how to sequence new antibody-drug conjugates (ADCs) for patients with HR-positive/HER2-negative breast cancer or TNBC. Two ADCs have been developed in parallel in both patient populations: T-DXd for HER2-low breast cancer and sacituzumab govitecan SG for TNBC, both outperformed standard of care.

    Source: dailynews.ascopubs.org
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of ASCO
      ASCO

      How do we decide on best treatment choice when 2 drugs (T-DXd & SG) w high efficacy are available to treat similar pt populations w no clear data on how to sequence them? @curijoey & @darioT_ explore recent trials & provide answers 👉 https://t.co/yHfsdQJYAS #ASCODailyNews #BCSM https://t.co/47Wdry3cvs

  • Mashup Score: 2
    Selective Sequential Use of ARSIs in Patients with Advanced Prostate Cancer - 8 month(s) ago

    There has been increasing discussion about the sequential use of ARSIs, particularly after progression on a prior agent. However, sequential ARSI use has demonstrated limited efficacy in most patients with advanced metastatic castration-resistant prostate cancer.

    Source: dailynews.ascopubs.org
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of ASCO
      ASCO

      .@DrRanaMcKay of @UCSanDiego for #ASCODailyNews on when to use an ARSI followed by another ARSI in #ProstateCancer: “Sequential use should be restricted to carefully selected clinical scenarios given limited clinical efficacy.” 👉 https://t.co/S4tXpPSOaf #pcsm #GUCSM https://t.co/nt5XXUJ544

  • Mashup Score: 0
    TALAPRO-2 in Practice: Considering Talazoparib Plus Enzalutamide For Patients With mCRPC and HRR Mutations - 9 month(s) ago

    In the phase 3 trial TALAPRO-2, the addition of the PARP inhibitor talazoparib to approved standard-of-care enzalutamide significantly prolonged rPFS (primary endpoint) as well as other endpoints, such as time to prostate-specific antigen progression, time to chemotherapy, and time to deterioration in the patient-reported global health status and the quality of life in patients with HRR–mutated mCRPC.

    Source: dailynews.ascopubs.org
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of ASCO
      ASCO

      ❔ Which patients w/ mCRPC & HRR mutations should be considered for talazoparib + enzalutamide? @PBarataMD unpacks the #ASCO23 TALAPRO-2 trial in context with other phase 3 trials for #ASCODailyNews ➡️ https://t.co/lTyEcLX4Df #prostatecancer #pcsm https://t.co/O5MU7jLPAe

  • Mashup Score: 3
    Considering Adjuvant CDK4/6 Inhibitors?: monarchE and NATALEE in Clinical Practice - 9 month(s) ago

    In monarchE, abemaciclib improved 2-year and 4-year invasive disease-free survival (IDFS), and in NATALEE, ribociclib improved 3-year IDFS; overall survival analyses for both trials remain immature. Thus, both abemaciclib and ribociclib are reasonable options in the adjuvant setting to reduce IDFS risk.

    Source: dailynews.ascopubs.org
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of ASCO
      ASCO

      After considering eligibility criteria, tox. profiles & data maturity, abemaciclib & ribociclib are reasonable options to reduce IDFS risk for HR-positive early #breastcancer based on NATALEE & monarchE data: https://t.co/MAIFnuaIzq @DrSGraff @marina_sharifi #ASCODailyNews #bcsm https://t.co/X0QDNoUwv5

  • Mashup Score: 3
    Targeting MYC-Driven Cancers With a Molecular Glue Degrader - 9 month(s) ago

    Molecular glue degraders offer new opportunities for therapeutic development beyond current applications of immunomodulatory drugs, which can expand to nonhematological solid tumors, inflammation, autoimmunity, neurologic disorders, and genetic and metabolic diseases.

    Source: dailynews.ascopubs.org
    Categories: Latest Headlines, Oncologists1
    Tweet Tweets with this article
    • Profile photo of FilipJankuMD
      FilipJankuMD

      Molecular glue degraders are disrupting undruggable and difficult-to-drug target space. Get acquainted!!! #OnToNewHeights @MonteRosaTx #ASCODailyNews @ASCO https://t.co/1Ungknk9qa

  • Mashup Score: 3
    Podcast: ASCO Breakthrough: Scientific Innovations and Emerging Technologies in Cancer Care - 9 month(s) ago

    Drs. Lillian Siu and Melvin Chua discuss scientific innovations, disruptive technologies, and novel ways to practice oncology that were featured at the 2023 ASCO Breakthrough meeting in Yokohama, Japan, including CRISPR and gene editing, CAR T-cell and adoptive cell therapies, as well as emerging AI applications that are poised to revolutionize cancer care. Dr. Melvin Chua: Hello, I’m Dr. Melvin Chua, your guest host of the ASCO Daily News Podcast today. I’m a radiation oncologist and I currently

    Source: dailynews.ascopubs.org
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of ASCO
      ASCO

      #ASCOBT23: @DrMLChua of the Nat’l Cancer Center Singapore and @lillian_siu of @pmcancercentre highlight oncology innovations and disruptive technologies transforming #CancerCare on the #ASCODailyNews Podcast. https://t.co/KSYPYw615C https://t.co/y669zHZjAE

Load More